Bartoszyk G D, Harting J, Minck K O
Merck KGaA, Dept. CNS-Research, Darmstadt, Germany.
J Pharmacol Exp Ther. 1996 Jan;276(1):41-8.
The putative, selective dopamine (DA) dopamine-2 autoreceptor agonist roxindole, which also exhibits serotonin-1A-agonistic and 5-hydroxytryptamine reuptake-inhibiting properties, was examined for its behavioral effects in rats and mice. Roxindole inhibited apomorphine-induced climbing in mice and stereotyped behavior in rats with ED50 values of 1.4 mg/kg s.c. and 0.65 mg/kg s.c., respectively, and inhibited conditioned avoidance response in rats (ED50 = 1.5 mg/kg s.c.). Thus roxindole showed a profile resembling those of the classical antipsychotic haloperidol and the atypical neuroleptic clozapine but differing from that of the DA autoreceptor agonist talipexole, which did not prevent apomorphine-induced behaviors. Unlike haloperidol, roxindole did not induce catalepsy in rats and mice. Investigations directed to the DA autoreceptor properties revealed that spontaneous motility of rats with normosensitive postsynaptic DA receptors was monophasically decreased by roxindole and talipexole, with a threshold dose of 0.0625 mg/kg s.c. for both compounds. In reserpinized rats with presumably hypersensitive postsynaptic DA receptors, roxindole only partially reversed reserpine-induced hypomotility (threshold dose: 0.25 mg/kg); talipexole re-established the activity level to that of normal rats. In contrast to apomorphine, roxindole did not induce and talipexole only marginally induced stereotyped behavior in normal rats. After administration of the DA dopamine-1 agonist SKF 38393, talipexole induced stereotyped behavior in rats, which indicated its activity at postsynaptic dopamine-2 receptors. In contrast, roxindole did not induce stereotyped behavior in rats when co-administered with SKF 38393. These results indicate that, compared with talipexole, roxindole possesses a greater selectivity for DA autoreceptors.
假定的选择性多巴胺(DA)多巴胺 - 2自身受体激动剂罗吲哚,它还具有5 - 羟色胺 - 1A激动和5 - 羟色胺再摄取抑制特性,对其在大鼠和小鼠中的行为效应进行了研究。罗吲哚抑制阿扑吗啡诱导的小鼠攀爬和大鼠刻板行为,皮下注射的半数有效剂量(ED50)分别为1.4 mg/kg和0.65 mg/kg,并抑制大鼠的条件性回避反应(ED50 = 1.5 mg/kg皮下注射)。因此,罗吲哚表现出与经典抗精神病药物氟哌啶醇和非典型抗精神病药物氯氮平相似的特征,但与DA自身受体激动剂泰必利不同,后者不能阻止阿扑吗啡诱导的行为。与氟哌啶醇不同,罗吲哚在大鼠和小鼠中不诱导僵住症。针对DA自身受体特性的研究表明,具有正常敏感性突触后DA受体的大鼠的自发运动性被罗吲哚和泰必利单相降低,两种化合物的阈剂量均为0.0625 mg/kg皮下注射。在推测具有超敏突触后DA受体的利血平化大鼠中,罗吲哚仅部分逆转利血平诱导的运动减少(阈剂量:0.25 mg/kg);泰必利将活动水平恢复到正常大鼠的水平。与阿扑吗啡不同,罗吲哚在正常大鼠中不诱导且泰必利仅轻微诱导刻板行为。给予DA多巴胺 - 1激动剂SKF 38393后,泰必利在大鼠中诱导刻板行为,这表明其在突触后多巴胺 - 2受体上具有活性。相比之下,罗吲哚与SKF 38393共同给药时在大鼠中不诱导刻板行为。这些结果表明,与泰必利相比,罗吲哚对DA自身受体具有更高的选择性。